First AD

Second AD

Current Treatment Approach to Relapsed/Refractory DLBCL

CD19-Targeted CAR T-Cell Therapy in Managing DLBCL

CD19-Targeted MAbs in Relapsed/Refractory DLBCL

Transplant Ineligibility: Anti-CD19 Combination Therapy

L-MIND Combination Therapy Dosing Schedule

Re-MIND Versus L-MIND Regimen

CD19 and CD20 Antibodies in Development

The Future of DLBCL Management

Newly Diagnosed Relapsed/Refractory DLBCL

CAR T: CD19-Targeted Therapy in R/R DLBCL

Treatment of R/R DLBCL: CD19-Targeted Monoclonal Antibodies

L-MIND Study: R/R DLBCL

Future Directions for R/R DLBCL

Precision Medicine

DLBCL

Experts in the management of diffuse large B-cell lymphoma (DLBCL) discuss the use of novel CD19-antibody mono- and combination therapies to treat relapsed/refractory subpopulations. 

Targeting CD19 in Diffuse Large B-Cell Lymphoma

Targeting CD19 in Diffuse Large B-Cell Lymphoma

Targeted Oncology